In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Sales of Novartis' CDK4/6 inhibitor Kisqali (ribociclib) were $787 million in Q3 2024, up 40 percent from Q3 2023. The agent, ...

This came after Novartis presented protocol amendment version 01 dated 01 December 2023 protocol no. CLEE011A2412B. LEE011 (ribociclib) is a selective cyclin dependent kinase inhibitor, a new class of ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology Kidney Week 2024 showing that patients with C3 glomerulopathy treated with oral ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Novartis. “Importantly, the NCCN Guideline recommendation of ribociclib in this broad population reaffirms the importance of offering eligible patients with early breast cancer, including those with ...

Also sluggish out of the blocks has been Kisqali (ribociclib), Novartis’ competitor to Pfizer's fast-growing breast cancer drug Ibrance (palbociclib), although this has started to come to life ...

Novartis. “Importantly, the NCCN Guideline recommendation of ribociclib in this broad population reaffirms the importance of offering eligible patients with early breast cancer, including those ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...